Biotech firm Biocon India Ltd today clarified that there were no deaths during the clinical trials conducted by it in relation to its recombinant human insulin. Biocon Chairman and Managing Director Kiran Mazumdar-Shaw told mediapersons that the trials were conducted strictly in accordance with protocol based on internationally accepted standards and with the consent of all volunteers involved. “We wish to categorically state that no deaths occurred during the clinical trials conducted in relation to r-human insulin by Biocon,” she said. “Not a single death occurred,” Shaw said.
